Skye Bioscience, Inc. — Director's Dealing 2018

Feb 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2018-02-16

Reporting Person: Emerald Health Sciences Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-16	Common Stock	P	15000000	—	Acquired	39000000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-16	Common Stock Warrants (right to buy)	$0.10	P	20400000	Acquired	2023-02-16	Common Stock (20400000)	Direct

Footnotes

F1: The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.